GlassScriptPhysician profile
Todd Jason Broder
NPI 1699849349
$1,588,617.91
in general payments reported to CMS, 2019-2025
19 companies · $423K in 2025
The $423K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103K · 2020: $49K · 2021: $68K · 2022: $202K · 2023: $325K · 2024: $419K · 2025: $423K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $632K · Consulting Fee: $200K · Travel and Lodging: $157K · Honoraria: $147K · Food and Beverage: $30K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $631,936.09 |
| Consulting Fee | $200,238.00 |
| Travel and Lodging | $156,960.02 |
| Honoraria | $147,067.50 |
| Food and Beverage | $30,347.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $396,511.50 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $395,823.89 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Axsome Therapeutics, INC. | $341,913.94 | 2023-2025 | Auvelity |
| Abbvie INC. | $216,754.16 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $123,764.39 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $61,626.70 | 2019-2025 | Lybalvi, Aristada |
| H. Lundbeck A S | $46,277.41 | 2024-2025 | Abilify Maintena |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,438.78 | 2020-2025 | Abilify Asimtufii, Abilify Maintena, Rejoyn |
| Neuronetics, INC. | $1,376.30 | 2019-2021 | |
| Livanova USA, INC. | $683.62 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $501.41 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $450.34 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $105.08 | 2024 | Fanapt |
| Idorsia Pharmaceuticals US INC | $100.94 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $96.19 | 2023-2024 | Uzedy, Austedo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $81.14 | 2019 | |
| Lundbeck LLC | $53.59 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Sage Therapeutics, LLC | $34.91 | 2024 | |
| Indivior INC. | $23.62 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Broder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.